Clinuvel Pharmaceuticals Limited's next confirmed earnings release is scheduled for February 23, 2027.
| Earnings Date | 2/23/2027 |
As of June 30, 2026, Clinuvel Pharmaceuticals Limited has 50.49M shares outstanding.
| Shares Outstanding | 50.49M |
As of June 30, 2026, Clinuvel Pharmaceuticals Limited maintains a current ratio of 14.81, meaning it holds 14.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.81 |
| Quick Ratio | 14.34 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 0.05 |
Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited posted a return on equity (ROE) of 13.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.14, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.01 indicates how many times Clinuvel Pharmaceuticals Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 13.21 |
| Return on Assets (ROA) | 11.97 |
| Return on Invested Capital (ROIC) | 10.47 |
| Return on Capital Employed (ROCE) | 13.14 |
| Inventory Turnover | 2.01 |
Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited recorded 9.51M in income tax expense. That works out to an effective tax rate of 28.84, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.98M, leaving 23.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 9.51M |
| Effective Tax Rate | 28.84 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 5.48 |
Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited generated 65.07M in revenue and converted that into 23.47M in net income, yielding earnings per share of 0.46. EBITDA reached 28.05M, while operating income came in at 27.37M.
| Revenue | 65.07M |
| Gross Profit | 54.13M |
| Operating Income | 27.37M |
| Pretax Income | 32.98M |
| Net Income | 23.47M |
| EBITDA | 28.05M |
| EBIT | 27.37M |
| Earnings Per Share (EPS) | 0.46 |
As of June 30, 2026, Clinuvel Pharmaceuticals Limited holds 174.43M in cash and equivalents against 1.34M in total debt, resulting in a net debt position of -174.43M. Total book value stands at 188.85M, with working capital of 183.68M providing operational flexibility.
| Cash & Cash Equivalents | 174.43M |
| Total Debt | 1.34M |
| Net Debt | -174.43M |
| Equity (Book Value) | 188.85M |
| Book Value Per Share | 3.74 |
| Working Capital | 183.68M |
These figures cover the twelve months ended June 30, 2026.
| Capital Expenditures | -1.11M |
Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited posted a gross margin of 83.18, reflecting its pricing power and cost economics. The operating margin of 42.06 and net profit margin of 36.07 provide insight into operational efficiency.
| Gross Margin | 83.18 |
| Operating Margin | 42.06 |
| Pretax Margin | 50.69 |
| Profit Margin | 36.07 |
| EBITDA Margin | 43.11 |
Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited paid dividends of 0.03 per share. The dividend payout ratio of 7.39 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.
| Dividend Per Share | 0.03 |
| Payout Ratio | 7.39 |
Already premium?